HER2-Targeting Affibody Equipped with Albumin-Binding Small Molecules for Radiotheranostics
Journal of Medicinal Chemistry · 12.11.2026 · 69 (21) · 26287-26301
DOI: 10.1021/acs.jmedchem.6c02269 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 14.10.2026. Verfasst von Weichen Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu610041, China. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Erb-b2 Receptor Tyrosine Kinases, Albumins, Small Molecule Libraries. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Sichuan University, National Science and Technology Major Project, West China Hospital, Sichuan University.
Abstract (Originalsprache)
HER2-targeting affibody radioprobes are often limited by rapid systemic clearance and excessive renal accumulation. Herein, we develop a modular chemical strategy to optimize the pharmacokinetic properties of affibodies through conjugation of small-molecule albumin-binding motifs (ABMs). Enabled by our selective S-glycosylation approach, ABMs were introduced via a sugar-based linker, allowing systematic modulation of probe behavior. Evaluation of sugar-modified variants revealed that sugar structure plays a critical role in regulating in vivo distribution, with the GalNAc-modified probe [68Ga]Ga-5c exhibiting favorable tumor-to-background contrast in PET/CT imaging. Further incorporation of ABMs afforded GalNAc-IPBA-functionalized affibody [177Lu]Lu-10a, which achieved an 17-fold extension of circulation half-life, reduced renal accumulation, and maintained efficient tumor targeting. Therapeutically, [177Lu]Lu-10a induced 86.25% tumor growth inhibition with minimal systemic toxicity. This study provides a modular strategy for overcoming pharmacokinetic limitations of affibody-based radiotheranostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu610041, China.
- School of Chemical Engineering, Sichuan University, Chengdu610041, China.
- Department of Nuclear Medicine and Clinical Nuclear Medicine Research Lab, West China Hospital, Sichuan University, Chengdu610041, China.
- Sichuan Provincial Engineering Research Center of Radiopharmaceutical Clinical Translation, Sichuan University, Chengdu, Sichuan610065, China.
- Sichuan Provincial Health Commission Key Laboratory of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan610041, China.
- Nuclear Power Institute of China , Chengdu610213, China.
ORCID-Profile: Wei Chen, Dawen Niu, Rong Tian, Yingwei Wang
Förderung
- Sichuan University
- National Science and Technology Major Project
- West China Hospital, Sichuan University
- Nuclear Power Institute of China
- Peking University
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Wang, W., Shen, A., Huang, M., Wang, R., Chen, W., Shen, G., Wang, Y., Geng, J., Chen, Z., Niu, D., Tian, R., & Wang, Y. (2026). HER2-Targeting Affibody Equipped with Albumin-Binding Small Molecules for Radiotheranostics. Journal of Medicinal Chemistry, 69(21), 26287-26301. https://doi.org/10.1021/acs.jmedchem.6c02269
Vancouver
Wang W, Shen A, Huang M, Wang R, Chen W, Shen G, et al. HER2-Targeting Affibody Equipped with Albumin-Binding Small Molecules for Radiotheranostics. Journal of Medicinal Chemistry. 2026;69(21):26287-26301. doi:10.1021/acs.jmedchem.6c02269
BibTeX
@article{Wang2026,
author = {Wang, Weichen and Shen, Ao and Huang, Mingxing and Wang, Rang and Chen, Wei and Shen, Guangming and Wang, Yaguang and Geng, Junshan and Chen, Zhao and Niu, Dawen and Tian, Rong and Wang, Yingwei},
title = {HER2-Targeting Affibody Equipped with Albumin-Binding Small Molecules for Radiotheranostics},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {21},
pages = {26287--26301},
doi = {10.1021/acs.jmedchem.6c02269}
}
EUVIMED